Ambalal Sarabhai Enterprises

₹35.83As of Sun 8 Nov 2026, 12:00 UTC

NSE:AMBALALSA—

Country India

PE (Fwd) 16.26

TSR 10Y CAGR —

Div yield —

ROE —

Pharmaceutical Preparations

Beta (5Y) 0.06

PE TTM 15.42

TSR TTM —

Mkt cap ₹2.730B

ROIC —

SE Grade™

—

Value

—

Quality

Moat

—

1Y Price

Reference

₹39

—

9.23%

—

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

2.025

Revenue₹B

—

1.976

1.710

1.743

1.973

2.025

2.063

0.61%

2.64

Revenue growth%

—

(13.46)

1.92

13.20

2.64

1.85

2.28

—

40.06

Gross margin%

—

41.12

38.99

41.17

40.03

40.06

39.99

40.06

9.38

Operating margin%

—

13.10

5.96

4.68

6.70

9.38

9.16

6.70

8.79

Net margin%

—

23.89

6.69

3.26

2.50

8.79

8.25

6.69

15.42

P/E ratio (avg)x

—

16.13

—

14.45

EV/EBITx

—

14.53

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

2.32

EPS₹

—

6.16

1.49

0.74

0.64

2.32

2.22

(21.64%)

—

261.05

EPS growth%

—

(75.76)

(50.38)

(13.20)

261.05

(4.38)

(31.79)

—

Bookvalue per sh₹

—

FCF per share₹

—

Dividend per sh₹

—

Div yield (avg)%

—

Payout ratio%

—

76.63

Shares (diluted)M

—

76.63

◌76.63

—

Buyback yield%

—

◌—

—

D/E ratiox

—

2.746

Enterprise value₹B

—

2.746

—

LT debt₹M

—

Peers (US$28.77M)

Cap (US$)

BDH Industries Limited

26.48M

21.24x

Everest Organics…

24.71M

44.25x

Accretion Pharmaceutic…

23.97M

17.15x

Vidipha Central…

28.38M

11.02x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

4.690

4.271

Own earn%

—

Sh yield%

—

Owners

Insiders/Inst%

4.06

0.63

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

5/5

Revenue growth years

3/4

EPS growth years

1/4

Dividend streakyrs

Op margin range%

5–13

$1 testx

—

Incr. ROIC%

—

Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures and markets pharmaceutical, molecular diagnostics, and electronic products in India and internationally.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹2.025B

0.61%

1.00×

Cost of revenue

₹1.214B

1.06%

1.02×

Operating expenses

₹621.4M

2.92%

1.09×

Revenue by region

No breakdown available

Reinvestment returns

n/m

Trend

Reinvestment rate

n/m

Return on capital

n/m

Spread over hurdle

n/m